#61
|
|||
|
|||
Öèòàòà:
"Ðåçóëüòàòû óäèâëÿþò, òàê êàê ïðåäïîëàãàëîñü, ÷òî ðîôåêîêñèá ñïîñîáåí ëèêâèäèðîâàòü äèñôóíêöèþ ýíäîòåëèÿ ñîñóäîâ è óìåíüøèòü ïðèçíàêè âîñïàëåíèÿ", çàÿâëÿþò âðà÷è èç Queen Elizabeth II Health Sciences Centre, Halifax, Canada. "Åùå áîëüøå ìû óäèâèëèñü, íå îáíàðóæèâ íèêàêîãî âëèÿíèÿ ïðåïàðàòà íà ôàêòîðû âîñïàëåíèÿ âêëþ÷àÿ Ñ- ðåàêòèâíûé áåëîê, âåäü ðîôåêîêñèá - ýòî ïðîòèâîâîñïàëèòåëüíûé ïðåïàðàò". òàê ÷òî íå çðÿ ïðîèçâîäÿò |
#62
|
||||
|
||||
Ñåé÷àñ íå ñìîãî ïðîöåòèðîâàòü, íî ìíå ïîïàæàëèñü íà ãëàçà äàííûå â êîòîðûõ ñîâìåñòíîå ïðèìåíåíèå COX-2 è àñïèðèíà ÏÎÂÛØÀËÎ âåðîÿòíîñòü íåáëàãîïðèÿòíûõ èñõîäîâ. Êðîìå ýòîãî åñòü äàííûå, ÷òî ïðèìåíåíèå àñïèðèíà (ïðàâäà áîëåå âûñîêèõ äîç) è ACE èíãèáèòèðîâ òàêæå ïîâûøàåò çàáîëåâàåìîñòü è ñìåðòíîñòü (òàê ÷òî åùå èññëåäîâàòü è èññëåäîâàòü...)
|
#63
|
|||
|
|||
Öèòàòà:
|
#64
|
||||
|
||||
Àëåêñ , ìíå òîæå ïîïàäàëîñü ýòî ñîîáùåíèå , íî â äàëüíåéøåì ýòà èäåÿ áûëà îïðîâåðãíóòà òåì æå àâòîðîì , êîòîðûé åå âûäàë ( âî âñÿêîñ ñëó÷àå , â öåëîì ïî ãðóïïå ÍÏÂÑ + àñïèðèí ) , à ïî ãðóïïå ñåëåêòèâíûõ èíãèáèòîðîâ èññëåäîâàíèå ñðàâíèòåëüíî íåäàâíî áûëî íà÷àòî .
Ýòîò âîïðîñ , åñòåñòâåííî , î÷åíü âàæåí , ïîñêîëüêó íà óðîâíå ïðàêòè÷åñêîé äåÿòåëüíîñòè òàêèå êîìáèíàöèè âîçíèêàþò íà êàæäîì øàãó . Èíôîðìàöèÿ áûëà íà ñàéòå Cîëüâåé
__________________
Ã.À. Ìåëüíè÷åíêî |
#65
|
||||
|
||||
Âîò, åñëè èíòåðåñíî, íåáîëüøîé îáçîð÷èê, íåìíîãî ñòàðåíüêèé, ïðàâäà:
Update on the Interaction Between Aspirin and Angiotensin-Converting Enzyme Inhibitors. James J. Nawarskas, Pharm.D. Îñíîâíûå âûâîäû: Interaction Between Aspirin and Enzyme Inhibitors from Pharmacotherapy Conclusion Although a potential aspirin-ACE inhibitor interaction has been the subject of much research over the past few years, relatively little remains known regarding its frequency and severity. Published studies are largely contradictory, although some extrapolations can be made: (1) low-dose aspirin (</= 100 mg/day) appears to cause fewer interactions than higher dosages; (2) the aspirin-ACE inhibitor interaction may occur in patients with hypertension, coronary artery disease, or heart failure; and (3) interindividual susceptibilities to the interaction may likely be present. Solutions to these issues will likely be found only in randomized, prospective, placebo-controlled trials. Âîò åùå îäèí: From Congestive Heart Failure Should Aspirin Be Used With Angiotensin-Converting Enzyme Inhibitors in Patients With Chronic Heart Failure? Posted 09/09/2003 Myung H. Park, MD Abstract Aspirin and angiotensin-converting enzyme (ACE) inhibitors are widely used in combination to treat a wide spectrum of cardiac disorders. Theoretically, a rationale for interaction between these two agents exists in the possible counterbalancing prostaglandin inhibiting actions of aspirin and the vasodilatory prostaglandin promoting effects of ACE inhibitors. Animal and human studies suggest such an interaction, but most are plagued by small numbers or retrospective designs. Large-scale trials are in progress to address this issue. Until then, the key factor in deciding whether a patient with ischemic heart disease on ACE inhibitor therapy should be placed on aspirin therapy may largely depend on the severity of heart failure. The more severe the heart failure, the more likely an appreciable interaction between aspirin and ACE inhibitors will occur. Treatment with either low-dose aspirin or with alternative agents, such as warfarin or clopidogrel, may be the best therapeutic approach for patients with severe systolic heart failure. Òàê, ÷òî ïîñìîòðèì, ÷òî ïîëó÷èòñÿ. Äóìàþ, ÷òî ïðîèçâîäèòåëè Plavix ïîìîãóò íàì ðàçîáðàòüñÿ ñ àñïèðèíîâûìè ïðîáëåìàìè ïðè ïîìîùè óâàæàåìûõ ñïèêåðîâ è êðàñèâûõ ïîñòåðîâ. Òåì íå ìååå ïîêà ñâîèì ïàöèåíòàì ñ ASA íàçíà÷àòü áóäó, íî òîëüêî ïî 81 mg. |
#66
|
||||
|
||||
Êñòàòè, ïî ïîâîäó Vioxx -- î÷åíü õîðîøèé ïðåïàðàò. Âñåì ðåêîìåíäóþ. ×àñòî ïðèìåíÿþ ïðè õðîíè÷åñêèõ áîëÿõ â ñïèíå â êîìáèíàöèè ñ
Vioxx 50, Neurontin 300 TID (ìîæíî áîëüøå), Ultram 50 Q 6h prn. Äîâîëüíî õîðîøèå ðåçóëüòàòû ïîëó÷àþòñÿ è ïàöèåíòû íå ïðèîáðåòàþò çàâèñèìîñòü îò íàðêîòèêîâ. Êðîìå òîãî, ïîñëåäíèå äàííûå -- ïðåäîïåðàöèîííîå íàçíà÷åíèå Vioxx ñíèæàåò ïîñòîïåðàöèîííûé áîëåâîé ñèíäðîì áåç ðèñêà êðîâîòå÷åíèÿ. |
#67
|
|||
|
|||
Àëåêñàíäð,
ß ìíîãî ðàç áûâàë â SUNY SB, ñòàæèðîâàëñÿ òàì.  óíèâåðñèòåòå ðàáîòàåò ìíîãî ìîèõ äðóçåé, äîáðûõ êîëëåã, ó÷èòåëÿ. Òàê ÷òî Suffolk è Nassau counties çíàþ íå õóæå Ïèòåðà.  Âàøåì ó÷ðåæäåíèè ïðàâäà íå áûâàë. ×òî äî õëàìèäèé, òî ñòåïåíü èõ "íåèçëå÷èìîñòè" â Ïèòåðå, äà è âî âñåé Ðîññèè ïðÿìî ïðîïîðöèîíàëüíà äâóì âåùàì: âðà÷åáíîé íèùåòå è ìåäèöèíñêîìó êðåòèíèçìó. È ïåðâîå è âòîðîå â Ðîññèè ïîêà â èçáûòêå, à çíà÷èò è íåðóêîòâîðíûé ïàìÿòíèê "íåèçëå÷èìîìó õëàìèäèîçó" ïî ïðåæíåìó ñòîèò. Ðàâíî ñîáñòâåííî êàê è òàêèì æå "íåèçëå÷èìûì" òðèõîìîíàäàì, ìèêîïëàçìàì ñ óðåàïëàçìàìè è åñòåñòâåííî õðîíè÷åñêîìó ïðîñòàòèòó, êàê "ãëàâíîé ïðè÷èíå" âñåõ ìóæñêèõ ïðîáëåì.  Ðîññèè êàê íèêîãäà àêòóàëüíî âûñêàçûâàíèå ê ñîæàëåíèþ ïîêîéíîãî àìåðèêàíñêîãî óðîëîãà E. Meares: "Õðîíè÷åñêèé ïðîñòàòèò - ìóñîðíàÿ êîðçèíà êëèíè÷åñêîãî íåâåæåñòâà". Ê ýòîìó îïÿòü æå ìîæíî äîáàâèòü - èçâå÷íàÿ êîðìóøêà ðîññèéñêîãî óðîëîãà. Íó ëàäíî, õâàòèò î ãðóñòíîì. À ñ âàìè ÿ ðàä âèðòóàëüíîìó çíàêîìñòâó. |
#68
|
||||
|
||||
Óàâæàåìûé Àëåêñåé!
Ó ìåíÿ ê âàì, êàê ê ÿðêîìó ïðåäñòàâèòåëþ ëåãàëüíîãî ìåäèöèíñêîãî áèñíåñà âîïðîñ, åñëè ìîæíî.  êàêîì ñåé÷àñ ñîñòîÿíèè íàõîäèòñÿ ëåãàëüíûé ðûíîê ìåäèöèíñêèõ óñëóã â Ïèòåðå? Ñóùåñòâóþò ëè ÷àñòíûå ìåäèöèíñêèå ãðóïïû è åñëè äà, òî êóäà îíè êëàäóò ñâîèõ ïàöèåíòîâ ïðè íåîáõîäèìîñòè ãîñïèòàëèçàöèè? Èìåþòñÿ ëè â íàëè÷èè ÷àñòíûå ãîñïèòàëè (íå õîçðàñ÷åòíûå îòäåëåíèÿ, à òàê, ÷òîáû îò è äî)? ß òóò áðîäèë ïî ñåòè è ñëó÷àéíî íàòêíóëñÿ íà ñàéò Ìåæäóíàðîäíîé êëèíèêè - òàê âîò îíè òàì ãîâîðÿò, ÷òî ñîáèðàþòñÿ ñòðîèòü ñâîé ñîáñòâåííûé ñòàöèîíàð(!!!). Âûõîäèò, äåíüãè ó íàðîäà íà ìåäèöèíó âñå-òàêè åñòü! Íå ñîâñåì ïîíÿòíî òîëüêî, ãäå îíè âîçüìóò ñòîëüêî ÷àñòíûì âðà÷åé, ÷òîáû ê íèì êëàñòü ñâîèõ ïàöèåíòîâ. Íî, ìîæåò áûòü ÿ íå ïðàâ è îíè ñîáðàþòñÿ ãîñïèòàëèçèðîâàòü òóäà òîëüêî ñâîèõ áîëüíûõ èç êëèíèêè? |
#69
|
|||
|
|||
Óâ. Àëåêñàíäð,
Ìîÿ êëèíèêà ïî ñóòè ÿâëÿåòñÿ ñîâåðøåííî ëåãàëüíîé private group practice. Ñâîèõ áîëüíûõ ìû ãîñïèòàëèçèðóåì â äå ôàêòî ÷àñòíûé ãîñïèòàëü (ìîæåò çíàåòå â Ïèòåðå ÖÌÑ×-122), òàì ìû èõ îïåðèðóåì, íàáëþäàåì ïîñëå îïåðàöèè. çàòåì îíè âîçâðàùàþòñÿ äëÿ íàáëþäåíèÿ â àìáóëàòîðíûé îôèñ. Êàê è â Øòàòàõ ìíîãèå îïåðàöèè äåëàåì êàê same day surgery, ïîñëå ðàäèêàëüíûõ ïðîñòàòýêòîìèé, â ÷àñòíîñòè, âûïèñûâàåì íà 3-5 äåíü. Äà, â Ïèòåðå åñòü íåñêîëüêî ïîëíîñòüþ ÷àñòíûõ êëèíèê. Ñòàöèîíàð Ìåæä. êëèíèêè áóäåò âòîðûì íà 100%÷àñòíûì. Îíè èñïîëüçóþò äàòñêèå èíâåñòèöèè, êîòîðûå íîñÿò âåñüìà äîëãîñð÷îíûé õàðàêòåð. Ïåðâûé ÷àñòíûé õèðóðãè÷åñêèé ñòàöèîíàð â Ïèòåðå (íå áóäó íàçûâàòü) åëå ñâîèäèò êîíöû ñ êîíöàìè. Ðûíîê î÷åíü äîõëûé. Ñòðàõêîìàïíèè - æàëêèå ìåíÿëüíûå êîíòîðû, à ó íàðîäà ìàëîâàòî äåíåã íà îïëàòó ðåàëüíîãî ëå÷åíèÿ. Ïîýòîìó òå îïåðàöèè, êîòîðûå â Øòàòàõ ñòîÿò ñêàæåì $ 25 000 - 30 000 ó íàñ ñòîÿò $ 3000 - 5000, ÷òî êîíå÷íî àáñîëþòíî íåðåíòàáåëüíî. |
#70
|
|||
|
|||
Öèòàòà:
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] "ÁÎËÅÓÒÎËßÞÙÈÅ ÏÐÅÏÀÐÀÒÛ ÎÏÀÑÍÅÅ, ×ÅÌ ÏÐÈÍßÒÎ Ñ×ÈÒÀÒÜ?" |
#71
|
||||
|
||||
Óâàæàåìaÿ Íàòàëüÿ!
Äðóãèå ïîäðîáíîñòè î êîêñèáàõ è ÍÏÂÑ ìîæåòå ïî÷åðïíóòü http://forums.rusmedserv.com/showthread.php?t=10282 ê ñ÷àñòüþ, íå âñå òàê ñòðàøíî, êàê îïèñûâàþò â ïåðèîäèêå, è ïîñòîÿííûé ïðèåì àñïèðèíà óæå íå òîëüêî ïðîô-êà ÑÑÇ, íî è îïóõîëåé òîëñòîãî êèøå÷íèêà. È ÷àñòîòà ÿçâ è ÆÊÊ íå ñòîëü óæ âåëèêà (äà è âûñîêîðèñêîâûõ ìîæíî ïðàçîëàìè "ïðèêðûòü"). |
#72
|
||||
|
||||
Èçúÿòèå Âèîêñà êîìïàíèåé Ïôàéçåð â ñåíòÿáðå 2004 ãîäà äëÿ âñÿõ ñòàëî íåîæèäàííîñòüþ. Ïðåïàðàò áûë ëþáèì ìíîãèìè â ÷àñòíîñòè çà åãî áîëåå âûñîêóþ ýôôåêòèâíîñòü ñî ñðàâíåíèþ ñ äðóãèìè êîêñèáàìè. Ðèñê ïðè ïðèìåíåíèè âèîêñà âîçíèêàåò ïðè ïîñòîÿííîì ïðèåìå áîëåå 6 ìåñ (èìåííî òîãäà íà÷èíàåò ðàçäåëàòüñÿ êðèâàÿ Êàïëàí-Ìåéåðà). Ïîñëåäîâàâøèå çà ýòèì ôóíäàìåíòàëüíûå èññëåäîâàíèÿ ïîêàçàëè, ÷òî íå âñå êîêñèáû îäèíàêîâû.  ÷àñòíîñòü øâåéöàðñêèìè èññëåäîâàòåëÿì óäàëîñü âûÿñíèòü, ÷òî Vioxx ïîïàäàåò â àêòèâíûé öåíòð COX-2 (êîòîðûé ðàïîëîæåí íà ìåìáðàíå "ëèöîì" ê íåé) ïðàêòè÷åñêè ïî ïîâåðõíîñòè áèëèïèäíîãî ñëîÿ, òîãäà êàê öåëåêîêñèá (öåëåáðåêñ) ïðîíèêàåò â ñàìó ìåìáðàíó è íå íàðóøàåò åå ïðîíèöàåìîñòü. Ïðè îáðàáîòêå Âèîêñîì êëåòî÷íîé ìåìáðàíû ïðîèñõîäèò óâåëè÷åíñèå åå ïðîíèöàåìîñòè äëÿ ñâîáîäíûõ ðàäèêàëîâ, ÷òî â ñâîþ î÷åðåäü ïîâûøàåò ïðîöåíò îêñèäèðîâàííûõ LDL, êîòîðûå ñòèìóëèðóþò ìàêðîôàãè (ôîðìèðóþòñÿ foam-cells è çàïóñêàåòñÿ âåñü êàñêàä âîñïàëåíèÿ â áëÿøêå). Öåëåêîêñèá íå íàðóøàÿ ïðîíèöàåìîñòü ìåìáðàíû äëÿ ñâîáîäíûõ ðàäèêàëîâ íå âûçàâàåò ñóùåñòâåííîãî ïîâûøåíèå îêèñëåííûõ LDL è íå ïîâûøàåò ñåðäå÷íî-ñîñóäèñòûé ðèñê â çíà÷èòåëüíîé ñòåïåíè, õîòÿ íåêîòîðûå èññëåäîâàíèÿ ïîêàçûâàþò, ÷òî íåêîòîðûé ðèñê âñå-òàêè ïðèñóòñòâóåò.
|